

This listing of claims will replace all prior versions and listings of claims in the application:

Claims 1-22. (cancelled).

23. (currently amended) A method for treating an eye comprising:
~~inserting into an eye a device comprising a piercing member and a cannula insertable~~
~~slidably disposed~~ within the piercing member, ~~the cannula having a length longer than the length~~
~~of the piercing member, wherein the step of inserting the device into the eye comprises~~ piercing
~~the piercing member is inserted into the sclera of the eye with the piercing member and the~~
~~device is advancing~~ the piercing member transconjunctivally through the sclera of the eye;
advancing the cannula through the piercing member towards a treatment site; and
treating the eye.
24. (currently amended) The method of claim 23 further comprising administering
~~wherein a therapeutic agent is administered to patient's~~ the eye through the cannula device.
25. (original) The method of claim 23 wherein the therapeutic agent is administered
subretinally to the patient's eye.
26. (currently amended) The method of claim 23 wherein the maximum cross-
sectional dimension of the piercing member portion of the device that pierces a patient's eye is
about 25 gauge or smaller.
27. (currently amended) A method of treating an eye, comprising:
piercing the eye with a piercing member and inserting the piercing member into the
vitreous humor of the eye, the piercing member having a proximal end and a distal end and a
lumen defined therebetween;

advancing a cannula through the piercing member lumen and beyond the distal end of the piercing member;

guiding the cannula through the vitreous humor of the eye to a treatment site; and
treating the treatment site.

28. (original) The method of claim 27 wherein the step of guiding the cannula to the treatment site comprises:

advancing the cannula within the eye until the distal end of the cannula is within the treatment site.

29. (original) The method of claim 27 or 28 wherein the step of treating the treatment site comprises:

supplying a medicament through the cannula and into the treatment site via the distal end of the cannula.

30. (previously presented) The method of claim 27 wherein the medicament is selected from the group consisting of genes, proteins, cells, small molecule pharmaceuticals and sterile solutions.

31. (previously presented) The method of claim 27 wherein the step of treating the treatment site comprises withdrawing material from the treatment site into the distal end of the cannula.

32. (previously presented) The method of claim 27 wherein the step of piercing the eye with a piercing member comprises inserting the distal end of the piercing member into and through the eye's sclera.

33. (previously presented) The method of claim 27 wherein the treatment site is selected from the group consisting of the eye's retina and the eye's vitreous humor.

34. (previously presented) The method of claim 27 wherein the treatment site is the eye's retina and the step of treating the treatment site comprises:

injecting medicament through the cannula and under the retina such that a dome-shaped retinal detachment is formed.

35. (previously presented) The method of claim 27 wherein the outer diameter of the piercing member is about 25 gauge or smaller.

36. (canceled)

37. (cancelled)

38. (previously presented) The method of claim 23 wherein the cannula comprises a polymer.

39. (canceled)

40. (canceled)

41. (currently amended) The method of claim 2439 wherein a steroid is administered to the eye.

42. (currently amended) The method of claim 2439 wherein a therapeutic agent is administered to the eye to treat retinal detachment, vascular occlusion, proliferative retinopathy, diabetic retinopathy, inflammation, degenerative disease, vascular disease or a tumor.

43. (currently amended) The method of claim 2439 wherein the therapeutic agent is administered sub-retinally within the eye.

44. (currently amended) The method of claim 2439 wherein the cannula is positioned within subretinal space of the eye and a therapeutic agent is injected from the cannula into the subretinal space.

45. (previously presented) The method of claim 23 further comprising removing material from the eye with the device.

46. (previously presented) The method of claim 45 wherein intravitreal fluid is removed from the eye.

47. (previously presented) The method of claim 23 wherein the outer diameter of the piercing member is small enough to allow the insertion site to self-seal following withdrawal of the piercing member from the eye.

48. (canceled)

49. (currently amended) The method of claim 27 wherein the piercing member device is inserted into the sclera of the eye.

50. (currently amended) The method of claim 27 wherein the piercing member is device advanced transconjunctivally through the eye.

51. (previously presented) The method of claim 27 wherein the cannula comprises a polymer.

52. (currently amended) The method of claim 27 wherein the treating comprises administering to the eye a therapeutic agent through the cannula to the eye with the device.

53. (previously presented) The method of claim 52 wherein a steroid is administered to the eye.

54. (previously presented) The method of claim 52 wherein a therapeutic agent is administered to the eye to treat retinal detachment, vascular occlusion, proliferative retinopathy, diabetic retinopathy, inflammation, degenerative disease, vascular disease or a tumor.

55. (previously presented) The method of claim 52 wherein the therapeutic agent is administered sub-retinally in the eye.

56. (previously presented) The method of claim 27 wherein the treating comprises removing material from the eye with the device.

57. (previously presented) The method of claim 56 wherein intravitreal fluid is removed from the eye.

58. (previously presented) The method of claim 52 wherein the cannula is positioned within subretinal space of the eye and a therapeutic agent is injected from the cannula into the subretinal space.

59. (previously presented) The method of claim 27 wherein the outer diameter of the piercing member is small enough to allow the insertion site to self-seal following withdrawal of the piercing member from the eye.

60. (currently amended) A method for treating an eye comprising:

inserting into an eye a device comprising an outer member having a proximal end and a distal end, and a cannula slidably disposed within the outer member, and within a piercing member at the distal end of the outer member, the cannula having a length extending or extendable beyond the outer member distal end, wherein the step of inserting the device is inserted into the eye comprises by piercing the eye with the piercing member and advancing the piercing member and at least a portion of the outer member into the eye;

advancing the cannula through the outer member and beyond the distal end into the eye;
and

treating the eye.

61. (previously presented) The method of claim 60 wherein the device is inserted into the sclera of the eye.

62. (previously presented) The method of claim 60 wherein the device is advanced transconjunctivally through the eye.

63. (previously presented) The method of claim 60 wherein the cannula comprises a polymer.

64. (previously presented) The method of claim 60 further comprising administering to the eye a therapeutic agent with the device.

65. (previously presented) The method of claim 64 wherein the therapeutic agent is administered through the cannula to the eye.

66. (previously presented) The method of claim 64 wherein a steroid is administered to the eye.

67. (previously presented) The method of claim 64 wherein a therapeutic agent is administered to the eye to treat retinal detachment, vascular occlusion, proliferative retinopathy, diabetic retinopathy, inflammation, degenerative disease, vascular disease or a tumor.

68. (previously presented) The method of claim 64 wherein the therapeutic agent is administered sub-retinally within the eye.

69. (currently amended) The method of claim 64 wherein the cannula is positioned within the subretinal space of the eye and a therapeutic agent is injected from the cannula into the subretinal space.

70. (previously presented) The method of claim 60 further comprising removing material from the eye with the device.

71. (previously presented) The method of claim 70 wherein intravitreal fluid is removed from the eye.

72. (previously presented) The method of claim 60 wherein the outer diameter of the outer member is small enough to allow the insertion site to self-seal following withdrawal of the piercing member from the eye.

73. (previously presented) The method of claim 60 wherein the outer member outer diameter is about 25 gauge or less.

74. (previously presented) The method of claim 23 wherein the piercing member creates an opening in the eye that is self-sealing.

75. (previously presented) The method of claim 27 wherein the piercing member creates an opening in the eye that is self-sealing.

76. (previously presented) The method of claim 60 wherein the piercing member creates an opening in the eye that is self-sealing.

77. (new) The method of claim 23, 27 or 60, further comprising the step of angling the piercing member, after the piercing member is within the vitreous humor of the eye in any direction so as to guide the cannula to any treatment site within the eye.

78. (new) The method of claim 77, wherein the piercing member is angled so as to treat multiple treatment sites with a single insertion of the piercing member into the eye.